In this study we utilized tumor lines derived from the Bcl-XL/Myc transgenic mouse model of PC malignancy to immunophenotypically characterize neoplastic Bz-sensitive and -resistant PCs in order to identify biomarkers associated with acquired and innate Bz resistance. The gene discussed is BCL2L1; the disease is pachyonychia congenita.